

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



AIM Vaccine Co., Ltd.
艾美疫苗股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 06660)

VOLUNTARY ANNOUNCEMENT
FULL INTEGRATION OF DEEPSEEK TO ACHIEVE STRATEGIC
UPGRADE OF “AI + INTELLIGENT VACCINE ENTERPRISE”

This announcement is made by AIM Vaccine Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company of the latest business developments of the Group.

As a leading vaccine enterprise in China, the Group actively responds to the national “AI +” industrial development strategy, fully deploys and integrates DeepSeek, and promotes the application of the DeepSeek R1 version in all business scenarios of the Group through a localization strategy. This aims to achieve “cost reduction, quality improvement and efficiency enhancement” throughout the entire lifecycle of vaccines.

To build an intelligent vaccine research and development system, the Group will leverage DeepSeek to obtain higher-quality vaccine candidates through the processes of discovery, design and manufacturing. By integrating multi-source heterogeneous data from various biological information databases and combining pre-trained protein language models with graph neural network architecture, we expect to achieve intelligent screening of antigen targets and dynamic analysis of conserved regions. Meanwhile, by connecting to real-time mutation monitoring data streams and utilizing long and short-term memory networks, the Group can predict the future direction of pathogen mutation, dynamically analyze conserved regions, and predict broad-spectrum antigenic epitopes. The Group will also leverage DeepSeek to combine generative models with deep learning techniques to optimize mRNA vaccine sequence design and stability. By predicting the secondary structure of mRNA, the Group can intelligently design efficient combinations of components based on the gene expression codon preference characteristics of the host cells to improve the mRNA stability and translation efficiency and generate optimal sequences. In addition, the Group is exploring the use of DeepSeek’s AI framework to optimize process parameters to enhance antigen yield and quality.

In the clinical aspect of the Group, we fully implement the integration of the DeepSeek R1 version with the clinical trial management system, EDC (Electronic Data Capture) system, central randomization system, pharmacovigilance system and laboratory management system, driving the entire vaccine clinical trial process from data collection, analysis to decision making to achieve intelligence, shortening the cycle of clinical trials, while enhancing data accuracy and compliance. This enables the researchers to focus more on core areas such as clinical project promotion, quality assessment, ethical judgment and humanistic care, providing technical support for the rapid marketing of vaccines. In addition to cost reduction, the efficiency and quality of clinical research can be greatly improved.

In terms of the Group's production and quality management, we fully implement the integration of the DeepSeek R1 version with the MES, LIMS, and SCADA systems, to facilitate deep learning of production, inspection data, and real-time monitoring data, and build predictive models for production and quality inspection management, with a view to optimizing production processes, enhancing efficiency, reducing production cycles, and lowering energy consumption. By leveraging AI to analyze production and inspection-related quality data, we can identify potential risks and achieve preventive quality control. This ensures that each batch of vaccines meets high compliance standards, further improving the stability, reliability, and consistency of vaccine quality.

In terms of the Group's marketing management, we fully deploy a comprehensive integration of the DeepSeek R1 version with the CRM system to further enhance the efficiency of data analysis and explore the value of data, and to provide data and decision-making support for the Company's operational management and strategic development. Based on the historical sales data and market demand trends, we utilize AI models to enable flexible analysis and accurate forecasting of market data. In addition, we fully integrate the DeepSeek R1 version in aspects such as corporate management, talent training and financial management, so as to build enterprise-level knowledge bases, further improving the Company's management standards.

The Group fully integrates the DeepSeek, and deeply penetrates AI technology into the entire industry chain, covering research and development, production, sales, and management, so as to provide AIM solutions for global immune prevention and control.

By order of the Board
AIM Vaccine Co., Ltd.

Mr. Yan ZHOU

*Chairman of the Board, Executive Director and
Chief Executive Officer*

Hong Kong, February 23, 2025

As at the date of this announcement, the Board of the Company comprises Mr. Yan ZHOU, Mr. Xin ZHOU, Mr. Wen GUAN, Mr. Shaojun JIA and Mr. Jie ZHOU as executive directors; Mr. Jichen ZHAO and Ms. Aijun WANG as non-executive directors; and Professor Ker Wei PEI, Mr. Hui OUYANG, Ms. Jie WEN and Mr. Xiaoguang GUO as independent non-executive directors.